Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

RVT-101 for Dementia with Lewy Bodies (HEADWAY-DLB)

Start: January 2016
End: December 2017
Enrollment: 240

What Is This Study About?

Researchers will test the efficacy and safety of the experimental drug RVT-101 in people with dementia with Lewy bodies, including its effect on visual hallucinations.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 85 Years

Must have:

  • Probable dementia with Lewy bodies
  • Mini-Mental State Examination score of 14-26 inclusive
  • Ability to comply with procedures for cognitive and other testing
  • Reliable caregiver who can report on participant's status throughout study

Must NOT have:

  • Atypical clinical features or clinical course that suggest diagnosis other than dementia with Lewy bodies
  • Any clinically relevant disease that makes the patient unsuitable for the study

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Who Is the General Study Contact?

For more information about this trial, contact Axovant Clinical Trials at 1-646-677-5778.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Axovant Sciences Ltd.

Source: ClinicalTrials.gov ID: NCT02669433

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health